ACTG Publications

TitleAuthorsDateJournalIssueVolume
Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.Sax, Paul E ; Tierney, Camlin ; Collier, Ann C ; Daar, Eric S ; Mollan, Katie ; Budhathoki, Chakra ; Godfrey, Catherine ; Jahed, Nasreen C ; Myers, Laurie ; Katzenstein, David ; Farajallah, Awny ; Rooney, James F ; Ha, Belinda ; Woodward, William C ; Feinberg, Judith ; Tashima, Karen ; Murphy, Robert L ; Fischl, Margaret A ; AIDS Clinical 2011 Oct 15J Infect Dis8204
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.Sax, Paul E ; Tierney, Camlin ; Collier, Ann C ; Fischl, Margaret A ; Mollan, Katie ; Peeples, Lynne ; Godfrey, Catherine ; Jahed, Nasreen C ; Myers, Laurie ; Katzenstein, David ; Farajallah, Awny ; Rooney, James F ; Ha, Belinda ; Woodward, William C ; Koletar, Susan L ; Johnson, Victoria A ; Geiseler, P Jan ; Daar, Eric S ; AIDS Clinical 2009 Dec 3N Engl J Med23361
AIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristics.Smurzynski, Marlene ; Collier, Ann C ; Koletar, Susan L ; Bosch, Ronald J ; Wu, Kunling ; Bastow, Barbara ; Benson, Constance A2008 Jul-AugHIV Clin Trials49
Anthropometric differences between HIV-infected individuals prior to antiretroviral treatment and the general population from 1998-2007: the AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLRT) cohort and NHANES.Atkinson, Benjamin E ; Krishnan, Supriya ; Cox, Gary ; Hulgan, Todd ; Collier, Ann C2013PLoS One68
Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1.Daar, Eric S ; Tierney, Camlin ; Fischl, Margaret A ; Sax, Paul E ; Mollan, Katie ; Budhathoki, Chakra ; Godfrey, Catherine ; Jahed, Nasreen C ; Myers, Laurie ; Katzenstein, David ; Farajallah, Awny ; Rooney, James F ; Pappa, Keith A ; Woodward, William C ; Patterson, Kristine ; Bolivar, Hector ; Benson, Constance A ; Collier, Ann C ; AIDS2011 Apr 5Ann Intern Med7154
Binge drinking is associated with differences in weekday and weekend adherence in HIV-infected individuals.De Boni, Raquel B ; Zheng, Lu ; Rosenkranz, Susan L ; Sun, Xin ; Lavenberg, Jeffrey ; Cardoso, Sandra W ; Grinsztejn, Beatriz ; La Rosa, Alberto ; Pierre, Samuel ; Severe, Patrice ; Cohn, Susan E ; Collier, Ann C ; Gross, Robert2016 Feb 1Drug Alcohol Depend159
Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.Dumond, Julie B ; Rigdon, Joseph ; Mollan, Katie ; Tierney, Camlin ; Kashuba, Angela D M ; Aweeka, Francesca ; Collier, Ann C2015 Dec 15J Acquir Immune Defic Syndr570
CD28-negative CD4+ and CD8+ T cells in antiretroviral therapy-naive HIV-infected adults enrolled in adult clinical trials group studies.Tassiopoulos, Katherine ; Landay, Alan ; Collier, Ann C ; Connick, Elizabeth ; Deeks, Steven G ; Hunt, Peter ; Lewis, Dorothy E ; Wilson, Cara ; Bosch, Ronald2012 JunJ Infect Dis11205
Changes in fat mitochondrial DNA and function in subjects randomized to abacavir-lamivudine or tenofovir DF-emtricitabine with atazanavir-ritonavir or efavirenz: AIDS Clinical Trials Group study A5224s, substudy of A5202.McComsey, Grace A ; Daar, Eric S ; O'Riordan, MaryAnn ; Collier, Ann C ; Kosmiski, Lisa ; Santana, Jorge L ; Fichtenbaum, Carl J ; Fink, Heidi ; Sax, Paul E ; Libutti, Daniel E ; Gerschenson, Mariana2013 Feb 15J Infect Dis4207
Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.Grant, Philip M ; Tierney, Camlin ; Budhathoki, Chakra ; Daar, Eric S ; Sax, Paul E ; Collier, Ann C ; Fischl, Margaret A ; Zolopa, Andrew R ; Balamane, Maya ; Katzenstein, David2013 Nov-DecHIV Clin Trials614
Effect of early versus deferred antiretroviral therapy for HIV on survival.Kitahata, Mari M ; Gange, Stephen J ; Abraham, Alison G ; Merriman, Barry ; Saag, Michael S ; Justice, Amy C ; Hogg, Robert S ; Deeks, Steven G ; Eron, Joseph J ; Brooks, John T ; Rourke, Sean B ; Gill, M John ; Bosch, Ronald J ; Martin, Jeffrey N ; Klein, Marina B ; Jacobson, Lisa P ; Rodriguez, Benigno ; Sterling, Timothy R ; Kirk, Grego2009 Apr 30N Engl J Med18360
Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort.Smurzynski, Marlene ; Wu, Kunling ; Letendre, Scott ; Robertson, Kevin ; Bosch, Ronald J ; Clifford, David B ; Evans, Scott ; Collier, Ann C ; Taylor, Michael ; Ellis, Ronald2011 Jan 28AIDS325
Factors associated with CD8+ T-cell activation in HIV-1-infected patients on long-term antiretroviral therapy.Zheng, Lu ; Taiwo, Babafemi ; Gandhi, Rajesh T ; Hunt, Peter W ; Collier, Ann C ; Flexner, Charles ; Bosch, Ronald J2014 Oct 1J Acquir Immune Defic Syndr267
Factors associated with remaining on initial randomized efavirenz-containing regimens.Smurzynski, Marlene ; Wu, Kunling ; Schouten, Jeffrey T ; Lok, Judith J ; Bosch, Ronald J ; Taiwo, Babafemi ; Johnson, Victoria Anne ; Collier, Ann C2013 Jul 31AIDS1227
Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial.Lorenzana, Sarah B ; Hughes, Michael D ; Grinsztejn, Beatriz ; Collier, Ann C ; Luz, Paula Mendes ; Freedberg, Kenneth A ; Wood, Robin ; Levison, Julie H ; Mugyenyi, Peter N ; Salata, Robert ; Wallis, Carole L ; Weinstein, Milton C ; Schooley, Robert T ; Walensky, Rochelle P2012 Jun 1AIDS926
HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status.Mollan, Katie ; Daar, Eric S ; Sax, Paul E ; Balamane, Maya ; Collier, Ann C ; Fischl, Margaret A ; Lalama, Christina M ; Bosch, Ronald J ; Tierney, Camlin ; Katzenstein, David ; AIDS Clinical Trials Group Study A5202 Team2012 Dec 15J Infect Dis12206
The impact of age on the prognostic capacity of CD8+ T-cell activation during suppressive antiretroviral therapy.Lok, Judith J ; Hunt, Peter W ; Collier, Ann C ; Benson, Constance A ; Witt, Mallory D ; Luque, Amneris E ; Deeks, Steven G ; Bosch, Ronald J2013 Aug 24AIDS1327
Impact of UGT1A1 Gilbert variant on discontinuation of ritonavir-boosted atazanavir in AIDS Clinical Trials Group Study A5202.Ribaudo, Heather J ; Daar, Eric S ; Tierney, Camlin ; Morse, Gene D ; Mollan, Katie ; Sax, Paul E ; Fischl, Margaret A ; Collier, Ann C ; Haas, David W ; DS Clinical Trials Group2013 Feb 1J Infect Dis3207
Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.Krishnan, Supriya ; Schouten, Jeffrey T ; Jacobson, Denise L ; Benson, Constance A ; Collier, Ann C ; Koletar, Susan L ; Santana, Jorge ; Sattler, Fred R ; Mitsuyasu, Ronald ; ACTG-ALLRT Protocol Team2011Oncology1-280
Long-term body composition changes in antiretroviral-treated HIV-infected individuals.Grant, Philip M ; Kitch, Douglas ; McComsey, Grace A ; Collier, Ann C ; Bartali, Benedetta ; Koletar, Susan L ; Erlandson, Kristine M ; Lake, Jordan E ; Yin, Michael T ; Melbourne, Kathy ; Ha, Belinda ; Brown, Todd T2016 Nov 28AIDS1830
Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals.Grant, Philip M ; Kitch, Douglas ; McComsey, Grace A ; Collier, Ann C ; Koletar, Susan L ; Erlandson, Kristine M ; Yin, Michael T ; Bartali, Benedetta ; Ha, Belinda ; Melbourne, Kathy ; Brown, Todd T2016 Aug 15J Infect Dis4214
Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection.Lok, Judith J ; Bosch, Ronald J ; Benson, Constance A ; Collier, Ann C ; Robbins, Gregory K ; Shafer, Robert W ; Hughes, Michael D ; ALLRT team2010 Jul 31AIDS1224
Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation.Grant, Philip M ; Kitch, Douglas ; McComsey, Grace A ; Dubé, Michael P ; Haubrich, Richard ; Huang, Jeannie ; Riddler, Sharon ; Tebas, Pablo ; Zolopa, Andrew R ; Collier, Ann C ; Brown, Todd T2013 NovClin Infect Dis1057
Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV.Schacker, Timothy W ; Bosch, Ronald J ; Bennett, Kara ; Pollard, Richard ; Robbins, Gregory K ; Collier, Ann C ; Gulick, Roy M ; Spritzler, John ; Mildvan, Donna ; AIDS Clinical Trials Group2010 May 1J Acquir Immune Defic Syndr154
No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT.Ribaudo, Heather J ; Benson, Constance A ; Zheng, Yu ; Koletar, Susan L ; Collier, Ann C ; Lok, Judith J ; Smurzynski, Marlene ; Bosch, Ronald J ; Bastow, Barbara ; Schouten, Jeffrey T ; ACTG A5001/ALLRT Protocol Team2011 Apr 1Clin Infect Dis752
Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.Smith, Kimberly Y ; Tierney, Camlin ; Mollan, Katie ; Venuto, Charles S ; Budhathoki, Chakra ; Ma, Qing ; Morse, Gene D ; Sax, Paul ; Katzenstein, David ; Godfrey, Catherine ; Fischl, Margaret ; Daar, Eric S ; Collier, Ann C ; AIDS Clinical Trials Group 5202 Study Team2014 FebClin Infect Dis458
Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial (ACTG A5234).Gross, Robert ; Zheng, Lu ; La Rosa, Alberto ; Sun, Xin ; Rosenkranz, Susan L ; Cardoso, Sandra Wagner ; Ssali, Francis ; Camp, Rob ; Godfrey, Catherine ; Cohn, Susan E ; Robbins, Gregory K ; Chisada, Anthony ; Wallis, Carole L ; Reynolds, Nancy R ; Lu, Darlene ; Safren, Steven A ; Hosey, Lara ; Severe, Patrice ; Collier, Ann C2015 Jan 1Lancet HIV12
Pretreatment factors associated with 3-year (144-week) virologic and immunologic responses to potent antiretroviral therapy.Bosch, Ronald J ; Bennett, Kara ; Collier, Ann C ; Zackin, Robert ; Benson, Constance A2007 Mar 1J Acquir Immune Defic Syndr344
The prevalence and incidence of neurocognitive impairment in the HAART era.Robertson, Kevin R ; Smurzynski, Marlene ; Parsons, Thomas D ; Wu, Kunling ; Bosch, Ronald J ; Wu, Julia ; McArthur, Justin C ; Collier, Ann C ; Evans, Scott R ; Ellis, Ron J2007 Sep 12AIDS1421
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.La Rosa, Alberto M ; Harrison, Linda J ; Taiwo, Babafemi ; Wallis, Carole L ; Zheng, Lu ; Kim, Peter ; Kumarasamy, Nagalingeswaran ; Hosseinipour, Mina C ; Jarocki, Bernadette ; Mellors, John W ; Collier, Ann C ; ACTG A5273 Study Group2016 JunLancet HIV63
Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.Fischl, Margaret A ; Collier, Ann C ; Mukherjee, A Lisa ; Feinberg, Judith E ; Demeter, Lisa M ; Tebas, Pablo ; Giuliano, Marina ; Dehlinger, Marjorie ; Garren, Kevin ; Brizz, Barbara ; Bassett, Roland2007 Jan 30AIDS321
Randomized study of dual versus single ritonavir-enhanced protease inhibitors for protease inhibitor-experienced patients with HIV.Collier, Ann C ; Tierney, Camlin ; Downey, Gerald F ; Eshleman, Susan H ; Kashuba, Angela ; Klingman, Karin ; Vergis, Emanuel N ; Pakes, Gary E ; Rooney, James F ; Rinehart, Alex ; Mellors, John W ; AIDS Clinical Trials Group Protocol A5143 Team2008 Mar-AprHIV Clin Trials29
Regulatory T cells and the risk of CMV end-organ disease in patients with AIDS.Weinberg, Adriana ; Bosch, Ronald ; Bennett, Kara ; Tovar-Salazar, Adriana ; Benson, Constance A ; Collier, Ann C ; Zolopa, Andrew ; Gulick, Roy M ; Wohl, David ; Polsky, Bruce ; Erice, Alejo ; Jacobson, Mark A2014 May 1J Acquir Immune Defic Syndr166
Relationship between CD4+ T-cell counts/HIV-1 RNA plasma viral load and AIDS-defining events among persons followed in the ACTG longitudinal linked randomized trials study.Smurzynski, Marlene ; Wu, Kunling ; Benson, Constance A ; Bosch, Ronald J ; Collier, Ann C ; Koletar, Susan L2010 SepJ Acquir Immune Defic Syndr155
Safety and immunogenicity of therapeutic DNA vaccination in individuals treated with antiretroviral therapy during acute/early HIV-1 infection.Rosenberg, Eric S ; Graham, Barney S ; Chan, Ellen S ; Bosch, Ronald J ; Stocker, Vicki ; Maenza, Janine ; Markowitz, Martin ; Little, Susan ; Sax, Paul E ; Collier, Ann C ; Nabel, Gary ; Saindon, Suzanne ; Flynn, Theresa ; Kuritzkes, Daniel ; Barouch, Dan H ; AIDS Clinical Trials Group A5187 Team2010PLoS One55
Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.Venuto, Charles S ; Mollan, Katie ; Ma, Qing ; Daar, Eric S ; Sax, Paul E ; Fischl, Margaret ; Collier, Ann C ; Smith, Kimberly Y ; Tierney, Camlin ; Morse, Gene D2014 DecJ Antimicrob Chemother1269
Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s).Tebas, Pablo ; Zhang, Jiameng ; Yarasheski, Kevin ; Evans, Scott ; Fischl, Margaret A ; Shevitz, Abby ; Feinberg, Judith ; Collier, Ann C ; Shikuma, Cecilia ; Brizz, Barbara ; Sattler, Fred ; AIDS Clinical Trials Group (ACTG)2007 Jun 1J Acquir Immune Defic Syndr245
Trends in multidrug treatment failure and subsequent mortality among antiretroviral therapy-experienced patients with HIV infection in North America.Deeks, Steven G ; Gange, Stephen J ; Kitahata, Mari M ; Saag, Michael S ; Justice, Amy C ; Hogg, Robert S ; Eron, Joseph J ; Brooks, John T ; Rourke, Sean B ; Gill, M John ; Bosch, Ronald J ; Benson, Constance A ; Collier, Ann C ; Martin, Jeffrey N ; Klein, Marina B ; Jacobson, Lisa P ; Rodriguez, Benigno ; Sterling, Timothy R ; Kirk, Greg2009 Nov 15Clin Infect Dis1049